NX-5948

Phase 3Small molecule

NNurix Therapeutics, Inc.

NX-5948 is one of 17 small molecule programs targeting Chronic Lymphocytic Leukemia (CLL). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Lymphocytic Leukemia (CLL)Recruiting

B-Cell LymphomaRecruiting

Chronic Lymphocytic Leukemia (CLL)Phase 2

Recruiting

B-Cell LymphomaPhase 3

Recruiting

Competition

Competitive Landscape

12 competitors in B-Cell Lymphoma

#DrugCompanyPhaseTrials

Jaypirca

Eli Lilly

Phase 3

1 2

Gazyva

Roche

Phase 2

3 3

COLUMVI

Roche

Phase 2

1 4

Epkinly

Genmab

Phase 2

1 5

Decadron

AAspen Global Incorporated

Phase 2

1 6

R-CHOP

IIncyte Biosciences Japan GK

Phase 2

1 7

NX-5948

NNurix Therapeutics, Inc.

Phase 3

2 8

Cytoxan

BBaxter Healthcare Corporation

Phase 1

2 9

Fludara

Sanofi

Preclinical

1 10

Rituxan

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Chronic Lymphocytic Leukemia (CLL)

NCT05131022

Q4 2030

Phase 2Recruiting

Chronic Lymphocytic Leukemia (CLL)

NCT07221500

Q2 2033

PreclinicalRecruiting

B-Cell Lymphoma

NCT07520006

Q3 2033

Phase 3Recruiting

B-Cell Lymphoma

NCT07516093

Clinical

Trials by Indication[1]

Chronic Lymphocytic Leukemia (CLL)2 trials

A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)

Recruiting·NNurix Therapeutics, Inc.·Phase 2·NCT07221500·100 enrolled

A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies

Recruiting·NNurix Therapeutics, Inc.·Phase 1·NCT05131022·572 enrolled

B-cell Lymphoma2 trials

A Phase 3, Randomized, Open-label, Multicenter Study of NX-5948 Versus Pirtobrutinib in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Recruiting·NNurix Therapeutics, Inc.·Phase 3·NCT07516093·620 enrolled

An Open-label, Multicenter Phase 1b/2 Study to Evaluate the Safety and Efficacy of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

Recruiting·NNurix Therapeutics, Inc.·Preclinical·NCT07520006·150 enrolled

Absorption1 trial

Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948

Completed·NNurix Therapeutics, Inc.·Phase 1·NCT06691828·8 enrolled

Unspecified1 trial

A Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Tolerability of NX-5948 Tablets Following Single and Multiple Ascending Doses, the Relative Bioavailability of NX-5948 Tablets Compared to Capsules, the Effect of NX-5948 on the QT Interval, the Effect of Food on the Pharmacokinetics of NX-5948, Drug-Drug Interactions With NX-5948, and the Intra-Subject Variability of the Bioavailability of NX-5948 Capsules

Completed·NNurix Therapeutics, Inc.·Phase 1·NCT06717269·223 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for NX-5948. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NX-5948 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NX-5948. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nurix Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNurix Therapeutics, Inc.

NX-5948

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q4 2030

Q2 2033

Q3 2033

Trials by Indication[1]

Chronic Lymphocytic Leukemia (CLL)2 trials

B-cell Lymphoma2 trials

Absorption1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News